Community-acquired pneumonia: what changed for patients

Pneumonia is a common reason for emergency attendance and hospital admission, yet its management involves more uncertainty than its familiar symptoms suggest. Guideline changes affect who receives imaging and laboratory tests, which antibiotic is chosen, how long treatment continues and what happens after discharge. For Australian patients, these decisions sit within a public system that balances rapid treatment, antimicrobial stewardship and equitable follow-up.

The new pneumonia guideline is most useful when it moves beyond a revised drug list. Diagnosis, severity, comorbidity and reliable follow-up shape outcomes just as much as antimicrobial selection. This review focuses on adults with community-acquired pneumonia, explains the clinically meaningful changes, and shows where local Australian pathways must shape implementation rather than simply copy overseas practice.

Why the pneumonia guidance changed

Community-acquired pneumonia begins outside hospital, usually within 48 hours of symptom onset; pneumonia developing after 48 hours in hospital follows a different pathway. Modern adult guidance places greater emphasis on severity assessment to select the care setting and initial treatment, while acknowledging the limits of any prediction score. The aim is to avoid unnecessary broad-spectrum treatment without increasing deaths or readmissions.

The timeline matters. When the Hospital Medicine 2017 conference convened at Mandalay Bay in Las Vegas in May 2017, adult recommendations still largely reflected the 2007 ATS/IDSA guideline. The major adult revision came in 2019, so it would be inaccurate to describe every current recommendation as a 2017 change. The conference supplied continuing education on clinical assessment and quality improvement, alongside professional networking. The durable shift is clear: diagnose deliberately, grade severity and review treatment early.

Diagnostic testing and imaging

Imaging has become more selective. A chest radiograph is often appropriate in hospital to confirm pneumonia and identify complications, particularly with hypoxaemia, confusion or significant comorbidity. For a clinically stable patient in the community, routine imaging may add little when the diagnosis is secure and management will not change. Selective imaging is not a reason to withhold radiography from every admitted patient.

Microbiological testing should answer a management question. Blood cultures are recommended in severe pneumonia, while urine antigen tests for pneumococcus or Legionella can help in severe illness or when the result will alter treatment. Viral testing may support isolation or antiviral decisions during influenza season, but respiratory swabs should not become an automatic package. Procalcitonin should not be used alone to decide whether to start or stop antibiotics.

Record what the imaging cannot explain. Breathlessness may reflect pulmonary oedema, COPD exacerbation or aspiration rather than new consolidation. Vaccination status, recent travel, medication exposures and risk factors for unusual organisms belong in the same assessment. For an admitted patient, oxygen requirement and physiological trends often reveal greater severity than the radiograph alone. A clear diagnosis and severity assessment provide a defensible basis for treatment and review.

Choosing antibiotics for community-acquired pneumonia

For otherwise healthy adults with non-severe pneumonia suitable for outpatient care, oral amoxicillin or doxycycline is commonly appropriate for typical bacterial infection. Macrolides are options when guideline indications, local resistance patterns or suspected atypical infection support them. Comorbidities can change that choice. Severe pneumonia generally needs combined coverage for streptococci and Legionella, such as a beta-lactam with a macrolide, or a respiratory fluoroquinolone when appropriate. Prior MRSA isolation, bronchiectasis and other risk factors may alter the plan.

Australian susceptibility data matter: the hospital antibiogram should inform inpatient choices, while community prescribing follows current national guidance. Paediatric pathways differ. When cultures identify a pathogen, narrow or change therapy according to the organism, clinical response and contraindications. Review prescriptions at 48 to 72 hours. A shorter course is not undertreatment when the patient is clinically stable and improving.

Comorbidity is not a footnote. Older adults, people with chronic lung or heart disease, and patients with poor nutrition or impaired swallowing may deteriorate despite standard therapy. The conference’s malnutrition documentation pearls explain why accurate records of comorbidities matter for treatment planning and length of stay. Australian medicine access also has two layers: the Pharmaceutical Benefits Scheme covers many community prescriptions, while admitted patients receive medicines through hospital formularies, with national systems managing shortages.

Severity, escalation and supportive care

Severity assessment guides admission, observation and escalation. CURB-65 and the Pneumonia Severity Index can support triage, but neither should override clinical judgement or deny admission to someone who looks unwell. Severe pneumonia is generally defined by respiratory failure or major organ dysfunction, with shock also requiring urgent sepsis care. Oxygen, fluids, prompt antibiotics and management of the cause remain central.

Corticosteroids are not routine for every severe presentation. The 2019 guideline was cautious about them, while later evidence supports considering them for selected intensive-care patients under current protocols. Busy emergency departments in Sydney and Melbourne also face winter respiratory demand, making clear escalation criteria and senior review important. A structured morning huddle method can surface deteriorating patients, unresolved investigations and pending antibiotic reviews without adding unnecessary meetings.

Australian hospitals can embed these decisions within medication-safety, infection-prevention and antimicrobial-stewardship systems, including the National Safety and Quality Health Service Standards and hand-hygiene requirements. Stewardship means the right drug for the right patient at the right time, not simply fewer antibiotic days. For Aboriginal and Torres Strait Islander patients, partnership with local Aboriginal health services, weight-based dosing and attention to access barriers are central to safe treatment.

Comparing outpatient and inpatient management

Treatment duration should follow the clinical course, not remain open by default. Many adults with non-severe pneumonia improve with about five days of appropriate antibiotics; severe disease often needs five to seven days, guided by response. Record an anticipated stop date and the features that justify extension. Chest imaging after recovery is not routinely required in low-risk patients. Persistent symptoms, a possible alternative diagnosis or incompletely excluded malignancy may justify review.

The boundary between outpatient and inpatient treatment is less absolute than it once was. Observation may suit selected stable patients, and oral therapy can replace intravenous treatment once intake is reliable and improvement is documented. The comparison below summarises the adult pathway; local protocols and individual assessment still determine care.

Discharge arrangements determine whether a short course remains safe. Patients need written warning signs and a direct route to reassessment, including urgent review for increasing breathlessness, confusion, cyanosis, inability to drink or persistent vomiting. Call 000 in an emergency; Healthdirect on 1800 022 222 assists with non-urgent health decisions. Remote patients in northern Australia may need follow-up arranged through a community clinic, Aboriginal Medical Service or telehealth-supported GP, because distance can turn a simple review into an overnight journey.

A practical checklist for safer pneumonia care

A guideline becomes useful when it produces specific decisions at admission and a clear review process afterwards. These checks translate the evidence into routine Australian care:

• Confirm pneumonia and consider plausible alternatives; distinguish community acquisition from pneumonia developing after admission.
• Record severity, oxygen needs and physiological trends; use a prediction score as support, not as an automatic admission rule.
• Order tests only when the result can change management, and avoid using procalcitonin as a stand-alone antibiotic decision.
• Choose antibiotics using the likely pathogens, local susceptibility data, allergies and risk factors for resistant organisms.
• Review treatment at 48 to 72 hours, narrow therapy when possible, document a stop date and extend only for a clinical reason.
• Give clear safety-net advice and arrange accessible follow-up, particularly for patients in remote areas or with barriers to primary care.

The practical takeaway is to make every pneumonia plan explicit: a supported diagnosis, a severity judgement, a time-limited antibiotic choice, a defined review point and a safe route back to care.